Obesity Drugs Show Early Promise Against Hormonal Disorder PMOS
A small but growing body of research suggests that GLP-1 drugs, the blockbuster medications primarily used for obesity and type 2 diabetes, may also offer effective treatment for polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder affecting 1 in 8 women worldwide. The early findings offer new hope for patients who have long faced limited treatment options, according to AP News.
A Family’s Long Struggle
Charlotte Touzalin was still a young teenager when she began struggling with weight gain, abnormal periods, and unwanted facial hair — the same puzzling symptoms that plagued her mother for decades. “I’d go home and I’d cry,” said Touzalin, now an 18-year-old college student from Colorado. “I didn’t understand why all this weight was coming back or why my friends didn’t have to shave their faces and I had to.”
Touzalin and her mother, Anne Schultz, were finally diagnosed with PMOS — a condition that was renamed from polycystic ovary syndrome (PCOS) earlier this year. Unlike her mother, Touzalin is entering young adulthood with new hope after participating in a study testing GLP-1 drugs as a treatment.
A Landmark Renaming
The name change from PCOS to PMOS, announced in May 2026, was the largest initiative ever to rename a medical condition. The effort took 14 years of global collaboration involving 56 patient and professional organizations and more than 22,000 survey responses. The Endocrine Society reported that the old name was misleading — it implied ovarian cysts that don’t actually exist and obscured the endocrine and metabolic nature of the disorder.
Professor Helena Teede, who led the renaming process, called it “a landmark moment that will lead to desperately needed worldwide advancements in clinical practice and research.” The Guardian noted that the new name better reflects the condition’s long-term, complex nature as a hormonal disorder affecting both reproductive and metabolic systems.
Promising Early Research
Dr. Melanie Cree, PMOS clinic director at Children’s Hospital Colorado, has led three studies testing GLP-1 drugs for PMOS. Early data published in June in the journal Fertility and Sterility showed that eight of 11 participants completing the trial lost at least 10% of their body weight, with a median weight loss of about 42 pounds and a median testosterone drop of 52%. Six women experienced more frequent periods, and four returned to monthly cycles.
“We need to do a better job taking care of it,” Cree said. “We are finding them incredibly effective and really exciting for improving symptoms in women with this condition.”
In Touzalin’s case, weekly semaglutide injections over 10 months slowed her abnormal hair growth and normalized her periods. “I became a happier version of myself,” she said. “I felt like a normal person.”
According to BioNews Central, Cree noted that “women with PMOS frequently face a frustrating choice between treatments that target reproductive symptoms and those that address metabolic health.” The early findings suggest injectable semaglutide may improve both.
Cautious Optimism in the Medical Community
While the results are encouraging, researchers caution that the evidence base remains limited. A systematic review published in the European Journal of Endocrinology rated the pooled findings as low certainty, and larger, longer-term trials are needed to confirm the durability of these benefits.
A newer trial published in August randomized 60 Chinese women and found that those taking tirzepatide combined with metformin lost significantly more weight and had higher rates of menstrual cycle recovery and pregnancy compared to metformin alone.
Insurance Barriers Remain
Despite the promising results, GLP-1 drugs are not FDA-approved for PMOS, making prescriptions off-label. Insurers frequently deny coverage, creating a significant barrier for patients.
“I use these medicines a great deal,” said Dr. Rana Malek, an endocrinologist with the University of Maryland Medical System.
Touzalin recently experienced this barrier firsthand. After her study participation ended in June, she lost access to the free medication and had to stop taking GLP-1s. Her mother is now fighting with their insurer to get her back on the treatment.
“It’s something that could help a lot of other people,” Touzalin said.
What’s Next
As research continues, the medical community watches closely to see whether larger trials confirm the early promise of GLP-1 drugs for PMOS, whether pharmaceutical companies will pursue FDA approval for this indication, and how the three-year transition to the PMOS name will affect patient care and research. For the millions of women affected by this condition, the developments represent a significant step forward in understanding and treating a disorder that has been misunderstood for far too long.